Genmab — September 2019
-
Novartis confirmed last week that Ofatumumab has Met its primary and secondary endpoints in two phase III studies. Full data will be presented at ECTRIMS later this month and provide a much clearer indication how the efficacy of these two agents compares.
-
-
Føj for en åbning da!

-
Det var så 100 kr. ned siden toppen i sidste uge!
-
@stockbull, fandme ikke nemt

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
